Corline Biomedical AB: Receives granted patent approval in China

Corline Biomedical AB («Corline» or the «company») has received notice from the chinese patent offices, that it intends to grant the company’s patent application no 2012800633094 — An agent to prevent thrombus formation. The patent application covers Corlines technology to treat and protect the blood vessels in the organs for transplantation («Renaparin») and for other applications in vivo and ex vivo in which blood vessels are treated with heparinkonjugat.

Based on the company’s heparinsubstans develops Corline product Renaparin® to improve kidney transplants, by preventing the ischemia/reperfusion injury, which occurs in up to 40 per cent of all kidney transplants and can lead to poor kidney function, and in the worst cases re-transplantation. The company estimates that the market potential amounts to SEK 4 billion on an annual basis for the treatment of the approximately 35 000 kidneys are transplanted in the EUROPEAN union and the united states. A planned clinical phase 1 study is 100% funded by the EUROPEAN commission through the Horizon 2020 appropriations of about 23 MILLION.

The chinese patent offices has announced that it intends to grant the company’s patent application which covers the general technology to protect the blood vessels with the company’s heparinsubstans. The patent also protects the specific application to the prevention of the ischemia/reperfusionsskador that may arise in connection with all types of helorgantransplantationer. The company has an approved patent for this application in the united states and has filed patent applications in Europe, corresponding to the application which is now approved in China.

Renaparin® is Corlines the first product in the field of organ transplantation. As additional intellectual property protection to the patent, the company has then previously received särläkemedelsstatus by both the us FDA and the european medicines agency (EMA) for this indication.

Henrik Nittmar, PRESIDENT of Corline Biomedical AB, comments

«The chinese patent is an important addition to our portfolio of intellectual property protection — we have a patent approved in the united states and särläkemedelsstatus both in the US and Europe. Our strategy is that, as a first step to develop Renaparin® for the established markets in the US and Europe. In the medium term, however, China come to pose a very significant market for Renaparin® and the additional products in the repair and protection of blood vessels that we have just embarked on the development of. The patent which is now approved in China is an important starting point for commercial activities and continued product development in new indications and is of course value in future potential licensieringsdiskussioner».

For questions, please contact

Henrik Nittmar, CEO

Telephone: 018-71 30 90

E-mail: henrik.nittmar@corline.se

Certified Adviser

Subsequently, the Brokerage is Corlines Certified Adviser.

This information is such information that Corline Biomedical AB is obliged to publish under the EU marknadsmissbruksförordning. The information was submitted, by the above contact person in the government, for publication on 11 July 2018.

Corline Biomedical AB

working with the endogenous substance heparin and has developed a portfolio of candidate drugs for use in conjunction with organ — and cell transplantation. The company is planning clinical studies in type 1 diabetes and kidney transplant, for which the Corline also has received särläkemedelsstatus («Orphan Drug»). Within the framework of a wholly owned subsidiary of Corline Pharma AB evaluated in vivo ad

 

 

180711_PM — Corline — Corline receives granted patent approval in China

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Corline Biomedical AB via Globenewswire

Добавить комментарий

^ Наверх